Typical and atypical antipsychotics - The misleading dichotomy: Results from the working group 'Drugs in Psychiatry' (AGATE)

Neuropsychobiology

Volumn 57, Issue 1-2, 2008, Pages 80-87

  Fischer Barnicol, David ^a   Lanquillon, Stefan ^a   Haen, Ekkehard ^a   Zöfel, Peter ^c   Koch, Horst J ^a,b,d   Dose, Matthias ^b   Klein, Helmfried E ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Hospital for Psychiatry and Psychotherapy   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Sächsisches Krankenhaus   (Germany)

Author keywords

Antipsychotics, typical, atypical; Extrapyramidal symptoms; Number needed to harm

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; BIPERIDEN; BROMPERIDOL; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MONOTHERAPY; NOMENCLATURE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED;

EID: 45549091515     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135641     Document Type: Article

References (45)

1. Nagendranath De: Neurological and mental symptoms produced by therapeutic dose of rauwolfia serpentina and mepacrine hydrochloride. Transactions of the Medical College Reunion Bengal 1944-1945;7:27-29.
2. Delay J DP: 38 cas de psychoses traitées par la cure prolongée et continue de 4560 R.P. Comptes rendus du congrès des médecines aliénistes et neurologistes de France et des pays de langue francaise 1952;50:503-513.
3. Haase HJ: Über Vorkommen und Deutung des psychomotorischen Parkinsonsyndroms bei Megaphen- bzw Largactil-Dauerbehandlung. Der Nervenarzt 1954;25:486-492.
4. Flügel F, Bente D: Das akinetisch-abuli sche Syndrom und seine Bedeutung für die pharmakologisch-psychiatrische Forschung. Deutsche Medizinische Wochenschrift 1956;51:2071-2074.
5. Haase HJ: Neuroleptics and the extrapyramidal system. Arzneimittelforschung 1978;28:1536-1537.
6. Bartholini G, Haefely W, Jalfre M, Keller HH, Pletscher A: Effects of clozapine on cerebral catecholaminergic neurone systems. Br J Pharmacol 1972;46:736-740.
7. Glazer WM: Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61(suppl 3):16-21.
8. Kane JM: Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001(suppl 4):S397-S403.
9. Haen E, Aigner JM, Jost D, Lippert E, Spindler P, Klein HE: Die Arzneimittelüberwachung in der Psychiatrie Bayern (AMÜPBayern). Arzneimitteltherapie 1999;17:93-96.
10. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S: Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000440.
11. Zar JH: Biostatistical Analysis, ed 4. Upper Saddle River, Prentice Hall, 1999.
12. Bland JM, Altman DG: Statistics notes: the odds ratio. BMJ 2000;320: 1468.
13. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589.
14. Altman DG: Confidence intervals for the number needed to treat. BMJ 1998;317:1309-1312.
15. Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
16. Tarsy D, Baldessarini RJ, Tarazi FI: Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
17. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA: The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75.
18. Fischer-Barnicol D, Lanquillon S, Koch H, Dose M, Klein HE: More or less typical neuroleptics. Nervenheilkunde 2002;21:379-385.
19. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW: Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995;118:52-56.
20. 2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160:303-309.
21. Licht RW, Gouliaev G, Vestergaard P, Frydenberg M: Generalisability of results from randomised drug trials: a trial on antimanic treatment. Br J Psychiatry 1997;170:264-267.
22. Black N: Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-1218.
23. Lima AR, Weiser KV, Bacaltchuk J, Barnes TR: Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2002;(3):CD003727.
24. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A: Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987;144:1148-1153.
25. Lavin MR, Rifkin A: Prophylactic antiparkinson drug use. I. Initial prophylaxis and prevention of extrapyramidal side effects. J Clin Pharmacol 1991;31:763-768.
26. WHO: Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry 1990;156:412-414.
27. Krausz M, Moritz SH, Naber D, Lambert M, Andresen B: Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. Eur Psychiatry 1999;14:84-88.
28. Kapur S, Remington G: Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-883.
29. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
30. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, et al: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-908.
31. 2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med 1993;23:791-797.
32. 2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Psychopharmacol Ser 1993;10:94-100.
33. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
34. 2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158:311-314.
35. Kapur S, McClelland RA, VanderSpek SC, Wadenberg ML, Baker G, Nobrega J, et al: Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 2002;13:831-835.
36. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S: Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42-49.
37. 2-dopamine receptor blockade: results from treatment with typical and atypical neuroleptics. Nervenarzt 2000;71:373-379.
38. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158: 360-369.
39. Dose M. New 'atypical' neuroleptics - the emperor's new clothes? Psychiatr Prax 2003;30:1-3.
40. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-950.
41. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-745.
42. Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
43. King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995;167:480-482.
44. Palmer BW, Heaton RK, Jeste DV: Extrapyramidal symptoms and neuropsychological deficits in schizophrenia. Biol Psychiatry 1999;45:791-794.
45. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P: Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999;19:203-208.